Prothena Corp Public Ltd Co
PRTA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$8.40
KIRA · Stoqly’s AI analyst, in plain words
- Prothena Corp Public Ltd Co had $9.7M of revenue in fiscal 2025, down 92.8% on the year before. Over five years, revenue changed +62.6% a year on average.
- Its operating margin was −2,216.4%, down 2,102.1 pts: of every 100 in sales, about −2,216 is left after running the business.
- Prothena Corp Public Ltd Co lost $244M in fiscal 2025.
Market cap
$438M
P/E
—
Revenue
$9.7M
Net income
−$244M
Free cash flow
—
Operating margin
−2,216.4%
Prothena Corp Public Ltd Co in 30 seconds · fiscal 2025
Are sales growing?
−92.8%
No. Sales fell 92.8% last year.
Does it make a profit?
−2,520.6%
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Prothena Corp Public Ltd Co does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- PROTHENA CORP PUBLIC LTD CO
- CIK
- 0001559053
Prothena Corp Public Ltd Co · PRTA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $201M | $53.9M | $91.4M | $135M | $9.7M |
| Revenue growth | 23,414.3% | −73.1% | 69.5% | 47.9% | −92.8% |
| Net interest income | $0.0M | $6.3M | $31.0M | $25.8M | $14.1M |
| Operating margin | 35.9% | −244.1% | −209.1% | −114.4% | −2,216.4% |
| Net income | $67.0M | −$117M | −$147M | −$122M | −$244M |
| Net margin | 33.4% | −217.0% | −160.9% | −90.5% | −2,520.6% |
| Diluted EPS | $1.38 | −$2.47 | −$2.76 | −$2.27 | −$4.53 |
| Cash | |||||
| Cash from operations | $92.6M | −$109M | −$134M | −$150M | −$164M |
| Share count change | 21.4% | −2.3% | 12.3% | 1.0% | 0.1% |
| Debt and strength | |||||
| Cash and short-term investments | $579M | $710M | $619M | $471M | $308M |
| Shareholders' equity | $466M | $622M | $561M | $487M | $280M |
| Current ratio | 17.5x | 14.3x | 11.2x | 10.0x | 7.7x |
| Returns and quality | |||||
| Return on equity | 20.6% | −21.5% | −24.8% | −23.3% | −63.6% |
| Return on tangible equity | 14.4% | −18.8% | −26.2% | −25.1% | −87.0% |
| Piotroski F-score | 6 | 2 | 2 | 1 | 1 |
| Altman Z'' | 6.3 | 5.8 | 3.4 | 5.3 | −6.0 |
Insiders bought, 12 months
$12.1M
1 insider
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
100%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Prothena Corp Public Ltd Co · PRTA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.40 a share, the company is worth $438M.
Source: SEC EDGAR XBRL filings (CIK 0001559053). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.